Dysplastic Nevus Syndrome (Atypical Mole Syndrome): What It Means
If a dermatologist has told you that you have multiple atypical moles, dysplastic nevus syndrome, or familial atypical multiple mole melanoma syndrome (FAMMM), you have one of the highest hereditary risk profiles for melanoma — and one of the most actionable. Lifetime melanoma risk in classic FAMMM is 60-90%, but with structured monitoring, the prognosis is dramatically better than for unscreened patients. This guide covers what the syndrome is, who has it, and the screening protocols that actually work.
What dysplastic nevus syndrome is
Dysplastic nevus syndrome (DNS) is a clinical pattern characterised by:
Multiple atypical moles (usually more than 50 total moles, with several showing atypical features under dermoscopy).
Atypical moles are larger (often >5-6mm), with irregular borders, multiple colours, and asymmetry that distinguishes them from common nevi.
Distribution often includes covered skin (back, scalp, buttocks) not just sun-exposed areas.
Familial Atypical Multiple Mole Melanoma syndrome (FAMMM) is the inherited form, defined by:
Dysplastic nevus syndrome features in the proband (the person being evaluated).
Melanoma in two or more first- or second-degree relatives.
Sometimes association with pancreatic cancer in the family (indicating a CDKN2A gene mutation).
Sporadic dysplastic nevus syndrome (without strong family history) carries elevated risk but lower than classic FAMMM.
The inheritance pattern in FAMMM is autosomal dominant, meaning each child of an affected parent has 50% chance of inheriting the syndrome.
Genetic basis
About 25-40% of FAMMM families carry a mutation in CDKN2A (also called p16 or INK4A). This gene normally suppresses tumour development by regulating cell cycle. Mutations remove this suppression, allowing melanocytes to accumulate damage more readily.
Other genes implicated:
CDK4 (rare).
BAP1 (associated with mesothelioma and uveal melanoma in addition to cutaneous melanoma).
MC1R (low-penetrance variants).
Genetic testing is available and can confirm or rule out CDKN2A mutations. Testing is recommended for families with multiple melanomas (3+ first-degree relatives), young-onset melanoma (under 40), or pancreatic cancer in the family alongside melanoma.
Knowing your CDKN2A status:
Guides screening intensity (more frequent dermatology, possibly pancreatic surveillance for affected families).
Informs reproductive decisions for affected families.
Can inform extended family members about their own risk.
Does not change overall life prognosis dramatically — well-monitored CDKN2A carriers can live full lives with excellent outcomes.
Diagnosis and assessment
Diagnosis is clinical, not genetic — most patients with DNS are diagnosed by dermatology examination and dermoscopy.
Dermatology evaluation:
Full-body skin examination, often with photography of all moles.
Dermoscopy of multiple atypical-appearing moles.
Clinical scoring (some centres use scoring systems like the Glasgow scoring or the dysplastic nevus syndrome criteria).
Family history — number of affected relatives, types of cancers, ages of diagnosis.
Genetic counselling consideration if FAMMM features present.
Serial photography for monitoring change — the gold standard for DNS patients. Total body photography at baseline plus dermoscopy of individual atypical moles, repeated at 6-12 month intervals, allows detection of change against a personal baseline.
Atypical moles themselves are not melanoma. Most never become melanoma — but the increased number provides more opportunities for melanoma to develop, and the monitoring requirement is higher.
Lifetime melanoma risk and what it means
FAMMM with CDKN2A mutation: 60-90% lifetime risk of cutaneous melanoma. Some carriers also have elevated risk of pancreatic cancer (10-20% lifetime in some families).
FAMMM without identified mutation but with family history pattern: 25-50% lifetime risk.
Dysplastic nevus syndrome without family history (sporadic DNS): 5-10x normal lifetime melanoma risk (compared to general population baseline of about 2%).
These are population-level numbers. Individual outcomes depend heavily on:
Quality of monitoring (regular dermatology vs no surveillance).
Lifestyle (sun exposure, tanning bed use).
Genetic specifics (CDKN2A penetrance varies by family).
Geographic factors (high-UV regions worsen outcomes).
The critical point: lifetime risk is high, but melanoma in monitored DNS patients is overwhelmingly caught at early curable stages. The outcomes for well-monitored DNS patients approach those of the general population for melanoma-specific mortality. The risk is real, the prognosis with surveillance is excellent.
Surveillance protocols that work
Standard recommended surveillance for diagnosed DNS:
Dermatology examination every 6 months. More frequent (every 3 months) if recently diagnosed or after recent excisions.
Total body photography at baseline and updated annually. Allows comparison over time.
Dermoscopy of all suspicious moles at each visit. Atypical moles get individual photo follow-up.
Monthly self-examination at home using ABCDE plus ugly duckling. Photograph any concerning lesions for next dermatology visit.
Low threshold for biopsy of any changing mole or any mole with new concerning features. DNS patients often have multiple biopsies over a lifetime — this is normal and protective.
Family screening:
First-degree relatives (parents, siblings, children) should also have dermatology evaluation, typically starting in adolescence.
Extended family screening for genetic mutation carriers if CDKN2A confirmed.
Pancreatic cancer surveillance (MRI or endoscopic ultrasound) for CDKN2A carriers in some centres, typically starting at age 40.
Lifestyle interventions:
Rigorous sun protection — SPF 50+ daily, hats, UPF clothing, no tanning beds ever.
Vitamin D from supplements rather than sun exposure.
Avoid living in extreme high-UV regions if possible (or compensate with extra protection).
With this protocol, lifetime melanoma incidence is reduced and melanomas that do develop are caught at curable stages. The data is clear: structured surveillance dramatically improves outcomes in DNS.
What to expect at dermatology visits
Each surveillance visit typically includes:
Full-body skin examination (10-15 minutes), undressed under good lighting, comparing with baseline photography.
Dermoscopy of atypical moles, especially those flagged in the photographic record as new or changing.
Photography of any concerning lesions for follow-up.
Discussion of any moles you've noticed at home.
Decisions about biopsy or excision of specific lesions.
Review of sun protection adherence and lifestyle factors.
For most DNS patients, several biopsies per year is normal. Each biopsy is a small procedure under local anaesthetic. Most come back as benign atypical moles or mildly to moderately dysplastic; a small minority show melanoma.
The psychological aspect of DNS surveillance is significant. Living with a known elevated risk and frequent biopsies is stressful. Many patients benefit from health anxiety support, structured monitoring schedules (rather than daily checking), and recognition that the surveillance itself is the protective intervention.
Do not skip visits because you're feeling well. The whole point of surveillance is catching things before they cause symptoms. Monitored DNS patients have excellent outcomes; unmonitored DNS patients face the full elevated risk.
If you have been told you have DNS, atypical mole syndrome, or FAMMM, surveillance every 6 months is the right baseline. Use our free ABCDE checker monthly between visits. Family members should also be evaluated if FAMMM features are present.
Start free ABCDE checkSources
Content based on clinical guidelines from the American Academy of Dermatology (AAD), British Association of Dermatologists (BAD), and peer-reviewed literature from JAAD, BJD, and JAMA Dermatology. Epidemiological data from NCI SEER and IARC GLOBOCAN. Full methodology